Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ShangPharma Corporation
Tech Transfer Roundup: MD Anderson Inks Set Of IO Deals Covering US, UK, Japan, China
Three separate agreements team the innovative cancer research center with Takeda, Artios/ShangPharma, and Ziopharm. Hoth continues busy deal-making year by licensing gene therapy from North Carolina State.
Asia Deal Watch: Ambrx, NovoCodex Partner On Second ADC Candidate, For CD70-Positive Cancers
Deal follows 2013 pact between Ambrx and NovoCodex parent Zhejiang Medicine for HER2-positive-directed ADC. Astellas teams with Pandion on pancreatic cancer and Takeda with MD Anderson on CAR NK therapies.
Finance Watch: A Bountiful November Harvest For Venture-Backed Biopharma
Five funds raised more than $1bn to back biotech firms; Arcus leads recent VC rounds with $107m GV-backed Series C; Celgene, Valeant sell notes to retire debt; and Alnylam cashes in on investor goodwill.
China IPO Roundup: Strong Spring Financings For Pharma And Biotech
China’s healthcare sector was back to actively raising proceeds from the capital markets in March and April, which witnessed more than 20 IPOs in total, with a stream of other listings being planned.
- Contract Research, Toxicology Testing-CRO
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.